Ad
related to: monoclonal antibody covid treatment
Search results
How 1301B7 Could Contribute To Advanced Vaccine Development
Forbes· 17 hours agoIn the ongoing Omicron era, a new COVID-19 antibody could renew optimism for urgently required...
Flu Breakthrough: Vanderbilt Scientists Discover Powerful New Weapon
SciTechDaily· 2 days agoVanderbilt University researchers have identified potent monoclonal antibodies against influenza B, showcasing a promising avenue for treatment and preventative ...
High Confidence AD Drug Donanemab Will Get FDA Panel Nod
Medscape· 4 days agoThe FDA delayed its decision on whether to approve the antiamyloid agent back in March, opting...
A Guide to Managing Covid This Summer
New York Times· 4 days agoHere’s what to know about symptoms, testing and treatment. KP.2, one of these variants, now accounts for 28.5 percent of cases, and data from the Centers...
The Push to Get More People Into Long COVID Studies
Medscape· 4 days agoLast spring, he enrolled in a clinical trial of a new long COVID therapy at Stanford University, and he's about to start another at the University of...
Anti-CD20 HGG Linked to Serious Infection Risk in MS
Medscape· 17 hours agoHypogammaglobulinemia is a known risk linked to B-cell–depleting therapies, but a real-world study has specified the risk and risk factors in multiple...
Inebilizumab 'MITIGATES' Flare Risk in IgG4-Related Disease
Medscape· 17 hours agoInebilizumab-cdon reduced the risk for flares by 87% in patients with IgG4-RD, the MITIGATE study showed.
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of...
Morningstar· 5 days agoGilead and Arcus Announce EtrumadenantPlus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer – In Cohort B of the ARC-9 mCRC Study, Etrumadenant ...
After key rare disease win, Annexon eyes $144 million raise - San Francisco Business Times
The Business Journals· 2 days agoAnnexon Inc. hopes to sell $125 million of stock following a late-stage clinical trial of a drug...
Small Business - Picayune Item | Picayune Item
The Picayune Item· 4 days agoGHENT, Belgium, June 04, 2024 (GLOBE NEWSWIRE) -- ExeVir Bio, a biotech company developing robust heavy chain-only antibody therapies for broad protection against infectious ...
